Mr. Alex Vasilkevich reports

BRIGHT MINDS BIOSCIENCES TO HOST VIRTUAL R&D DAY ON MAY 20, 2025; PROGRAM HIGHLIGHTS INCLUDE AN OVERVIEW OF ABSENCE SEIZURES AND THE BMB-101 PHASE 2 STUDY

Bright Minds Biosciences Inc. will host a virtual R&D (research and development) day on Tuesday, May 20, 2025, from 10 a.m. ET to 11:30 a.m. ET.

The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned key opinion leaders (KOLs) in epilepsy research, as well as an overview of the company's breakthrough study, an open-label phase 2 clinical trial evaluating the safety, tolerability and efficacy of BMB-101 in adult patients with classic absence epilepsy and developmental and epileptic encephalopathy (DEE). Attendees will have the opportunity to ask questions at the conclusion of the program.

Webcast information

The Bright Minds Biosciences virtual R&D day will be webcast live and a replay will be available after the event by visiting the investors section of the company's website and selecting events and presentations.

Date and time:  Tuesday, May 20, 2025, 10 a.m. ET to 11:30 a.m. ET

About Bright Minds Biosciences Inc.

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. The company's pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

We seek Safe Harbor.